We have located links that may give you full text access.
JOURNAL ARTICLE
RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
Differentiation of ischemic from nonischemic cardiomyopathy with positron emission tomography.
American Journal of Cardiology 1987 June 2
This study was undertaken to determine whether positron emission tomography (PET) performed after the intravenous injection of 11C-palmitate permits differentiation of patients with ischemic from those with nonischemic dilated cardiomyopathy. PET was performed after intravenous injection of 11C-palmitate in 10 patients with ischemic and in 10 with nonischemic dilated cardiomyopathy. Regions of homogeneously severely depressed accumulation of 11C-palmitate, representing 15% or more of the expected myocardial cross-sectional area, were observed in 8 of 10 patients with ischemic but in none of 10 patients with nonischemic cardiomyopathy. Patients with nonischemic cardiomyopathy had marked spatial heterogeneity of the accumulation of palmitate throughout the left ventricular myocardium, whereas most tomographic sections from patients with ischemic cardiomyopathy accumulated 11C-palmitate more homogeneously in regions exclusive of discrete defects indicative of remote infarction. Thus, a larger number of discrete noncontiguous regions (17 +/- 5 compared with 12 +/- 4, p less than 0.001) and greater reduction of average 11C-palmitate content (59 +/- 6 compared with 64 +/- 10% maximal myocardial radioactivity, p less than 0.05) were seen in the tomographic reconstructions from patients with nonischemic than in those from patients with ischemic cardiomyopathy. These findings support the hypothesis that multiple myocardial infarctions underlie the process seen as dilated cardiomyopathy in patients with coronary artery disease. Our findings indicate that PET permits differentiation of patients with ischemic from those with nonischemic cardiomyopathy.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app